Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Short term Debt (2016 - 2024)

Cytosorbents' Short term Debt history spans 7 years, with the latest figure at $2.5 million for Q1 2024.

  • Quarterly results put Short term Debt at $2.5 million for Q1 2024, changed N/A from a year ago — trailing twelve months through Mar 2024 was $2.5 million (changed N/A YoY), and the annual figure for FY2023 was $2.5 million, changed.
  • Short term Debt for Q1 2024 was $2.5 million at Cytosorbents, roughly flat from $2.5 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $9.2 million in Q3 2020 to a low of $833333.0 in Q3 2023.
  • The 3-year median for Short term Debt is $3.3 million (2020), against an average of $4.3 million.
  • Peak annual rise in Short term Debt hit 700.0% in 2020, while the deepest fall reached 150.0% in 2020.
  • Year by year, Short term Debt stood at $9.2 million in 2020, then tumbled by 72.73% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024.
  • According to Business Quant data, Short term Debt over the past three periods came in at $2.5 million, $2.5 million, and $833333.0 for Q1 2024, Q4 2023, and Q3 2023 respectively.